Versantis, a Zurich, Switzerland-based clinical-stage biotech company developing therapies for rare liver and pediatric diseases, closed a CHF16m Series B financing.
The round was led by Swisscanto Invest by Zürcher Kantonalbank with participation from Esperante Ventures, investiere, existing investors Redalpine HealthEquity, and Zürcher Kantonalbank Start-up Finance.
With the closing of this financing round, Dr. Robert Schier, Investment Director PE/VC Health-Tech at Swisscanto Invest, will join Versantis’ Board of Directors.
The company intends to use the fudns to advance clinical development of novel therapeutics for liver diseases. In particular, the funds will accelerate the completion of ongoing Phase 1b studies with VS-01 and advance its clinical development up to clinical proof-of-efficacy (phase 2a) in 2 indications.
Led by Dr. Vincent Forster, CEO and co-founder, and Dr. Meriam Kabbaj, COO and co-founder, Versantis is a clinical-stage biotech company focused on the development of orphan drugs in liver diseases and pediatric inborn errors of metabolism. The company is pursuing innovative therapies for the acute care of serious liver conditions based on its proprietary liposomes-based detoxification platform technology.
Its lead candidate, VS-01, is currently being evaluated in first-in-human clinical trials, with outcomes expected mid-2020.